U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06980649) titled 'Study of BHV-1300 in Graves' Disease' on May 12.
Brief Summary: The purpose of this study is to determine if BHV-1300 is a safe and effective treatment in participants with Graves' Disease.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Graves Disease
Intervention:
DRUG: BHV-1300
BHV-1300 is delivered subcutaneously (SC)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biohaven Therapeutics Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....